Aldeyra Therapeutics — Top-Line Results from Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy

13 slides

Aldeyra Therapeutics · Health & Biotech · 2022

Download this PDF

Enter your email to download this deck. We’ll also send occasional updates about new decks.

PPT coming soon -

PPT coming soon

Get an email when PowerPoint downloads are available.

About this deck

Explore the presentation slide by slide for its financial analysis, transaction details, and investor communications.

Read moreRead less
Company
Aldeyra Therapeutics
Industry
Health & Biotech
Year
2022
Slides
13
Company
Aldeyra Therapeutics
Industry
Health & Biotech
Year
2022
Slides
13